The acute mononucleosis study at the University of Minnesota will mark the first of several planned studies of valomaciclovir against Epstein-Barr virus (EBV) related diseases.
Fred Volinsky, CEO of Epiphany, said: “This initial study in acute mononucleosis will set the stage for broader indications involving EBV as an etiologic agent.”